Annual Shareholders Equity
$245.91 M
+$322.73 M+420.09%
31 December 2023
Summary:
Enliven Therapeutics annual stockholders equity is currently $245.91 million, with the most recent change of +$322.73 million (+420.09%) on 31 December 2023. During the last 3 years, it has risen by +$266.21 million (+1311.12%). ELVN annual shareholders equity is now at all-time high.ELVN Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Shareholders Equity
$288.40 M
-$16.53 M-5.42%
30 September 2024
Summary:
Enliven Therapeutics quarterly stockholders equity is currently $288.40 million, with the most recent change of -$16.53 million (-5.42%) on 30 September 2024. Over the past year, it has increased by +$26.66 million (+10.18%). ELVN quarterly shareholders equity is now -9.23% below its all-time high of $317.71 million, reached on 31 March 2024.ELVN Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ELVN Shareholders Equity Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +420.1% | +10.2% |
| 3 y3 years | +1311.1% | +772.5% |
| 5 y5 years | - | - |
ELVN Shareholders Equity High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +420.1% | -9.2% | +475.4% |
| 5 y | 5 years | at high | +420.1% | -9.2% | +475.4% |
| alltime | all time | at high | +420.1% | -9.2% | +475.4% |
Enliven Therapeutics Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $288.40 M(-5.4%) |
| June 2024 | - | $304.93 M(-4.0%) |
| Mar 2024 | - | $317.71 M(+29.2%) |
| Dec 2023 | $245.91 M | $245.91 M(-6.1%) |
| Sept 2023 | - | $261.75 M(-6.2%) |
| June 2023 | - | $278.99 M(-4.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $291.42 M(-479.3%) |
| Dec 2022 | -$76.83 M(+79.1%) | -$76.83 M(+12.8%) |
| Sept 2022 | - | -$68.10 M(+58.8%) |
| Dec 2021 | -$42.89 M(+111.2%) | - |
| Dec 2021 | - | -$42.89 M |
| Dec 2020 | -$20.30 M | - |
FAQ
- What is Enliven Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for Enliven Therapeutics?
- What is Enliven Therapeutics annual shareholders equity year-on-year change?
- What is Enliven Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Enliven Therapeutics?
- What is Enliven Therapeutics quarterly shareholders equity year-on-year change?
What is Enliven Therapeutics annual stockholders equity?
The current annual shareholders equity of ELVN is $245.91 M
What is the all time high annual shareholders equity for Enliven Therapeutics?
Enliven Therapeutics all-time high annual stockholders equity is $245.91 M
What is Enliven Therapeutics annual shareholders equity year-on-year change?
Over the past year, ELVN annual stockholders equity has changed by +$322.73 M (+420.09%)
What is Enliven Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of ELVN is $288.40 M
What is the all time high quarterly shareholders equity for Enliven Therapeutics?
Enliven Therapeutics all-time high quarterly stockholders equity is $317.71 M
What is Enliven Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, ELVN quarterly stockholders equity has changed by +$26.66 M (+10.18%)